NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

Interventional Procedures Advisory Committee (IPAC) meeting minutes

**Minutes:** Confirmed

**Date and time:** Thursday 9th June 2022

**Location:** Zoom

# Committee members present

1. Professor Tom Clutton-Brock [Chair] Present for all items
2. Professor Colin Howie [Vice Chair] Present for all items
3. Dr Charlotta Karner Present for all items
4. Ms Dawn Lee Present for items 1 – 8
5. Dr Duncan McPherson Present for all items
6. Mr James Tysome Present for all items
7. Dr Jon Bell Present for all items
8. Miss Karen Nugent Present for all items
9. Mr Mahmoud Elfar Present for all items
10. Mr Marwan Habiba Present for all items
11. Professor Matt Bown Present for all items
12. Dr Ruchika Gupta Present for all items
13. Mrs Sally Brearley Present for all items
14. Dr Stuart Smith Present for all items
15. Professor Tim Jackson Present for all items
16. Ms Veena Soni Present for all items

**Apologies**

1. Professor Dhiraj Tripathi
2. Mr Jonathan Anderson
3. Mr Kieran Murphy
4. Ms Maria Parsonage
5. Mr Matthew Metcalfe
6. Dr Tim Kinnaird
7. Dr Jurjees Hasan

# NICE staff present:

Dr Alan Ashworth – Consultant Clinical Advisor, IPP

Amy Crossley – HTA Adviser, IPP

Anastasia Chalkidou – Associate Director, IPP

Andrew Kenyon – Programme Manager, IPP

Charlie Campion – Project Manager, IPP

Deonee Stanislaus – Coordinator, IPP

Emilene Coventry – Senior Medical Editor, IPP

Emma McCarthy – Associate Health Technology Assessment Analyst

Helen Gallo – Senior Health Technology Assessment Analyst

Professor Kevin Harris – Programme Director & Consultant Clinical Advisor, IPP

Lakshmi Mandava – Health Technology Assessment Analyst

Lyn Davies – Coordinator, Corporate Office

Tom Palmer – Health Technology Assessment Analyst

Xia Li – Health Technology Assessment Analyst

# External group representatives present:

Gianluca Casali, Medical Director UK/Ireland, Johnson & Johnson Medical Limited Present for item #3

Janet DeMarchi, Medical Science Liaison, Johnson & Johnson Medical Limited Present for item #3

Pascal Garcia, Medical Affairs and Education Manager, Boston Scientific Present for item #4

Neil Turner, Business Development Manager, Boston Scientific Present for item #4

Nicholas Cooper, Palette Life Sciences Present for item #9

Tom Brown, Consultant UK & Ireland, Palette Life Sciences Present for item #9

Dr Ronald Morton, VP & Chief Medical Officer, Urology and Pelvic Health, Boston Scientific Present for item #9

Emily Woodward, Director Health Economics and Market Access, Urology and Pelvic Health EMEA, Boston Scientific Present for item #9

Andrew Slack, Episurf Present for item #7

Katarina Flodström, Episurf Present for item #7

# Clinical & patient experts present:

Mr Saj Wajed, Consultant Upper GI Surgeon, Royal Devon & Exeter Hospital Present for item #3

Ben Knight, Consultant, Portsmouth Hospital University Trust Present for item #3

Dhiren Nehra, Consultant Upper GI Surgeon, Epsom & St. Helier NHS Trust Present for item #3

Ron McCulloch, Consultant Paediatric Surgeon, The London Podiatry Centre Present for item #4

Dr Mohamed Abdelghani, Consultant Psychiatrist, Camden & Islington NHS Foundation Trust Present for item #6

1. Introduction to the meeting
   1. The chair welcomed members of the committee and other attendees present to the meeting.
2. News and announcements
   1. None.
3. NNP of IP973/3 Laparoscopic insertion of a magnetic titanium ring for gastro-oesophageal reflux disease
   1. Part 1 – Open session
      1. The chair welcomed the invited clinical and patient experts, external group representatives, members of the public and company representatives from Johnson & Johnson Medical Limited.
      2. The chair asked all committee members to declare any relevant interests in relation to the item being considered.

* No conflicts of interest were declared for the technology.
* The Committee was asked whether there were any specific equalities issues to consider in relation to this procedure.
  + 1. The Chair then introduced Charlotta Karner, who gave a presentation on the safety and efficacy of Laparoscopic insertion of a magnetic titanium ring for gastro-oesophageal reflux disease.
  1. Part 2 – Closed session

Company representatives, clinical and patient experts and members of the public were asked to leave the meeting at 10:11.

* + 1. The committee then made its provisional recommendations on the safety and efficacy of the procedure. The committee decision was reached by consensus..
    2. The committee asked the NICE technical team to prepare the Consultation Document [IPCD] in line with their decisions.

A document explaining the draft recommendations will be available here: <https://www.nice.org.uk/process/pmg28/chapter/draft-recommendations>

1. NNP of IP1852 Percutaneous image-guided cryoablation of peripheral neuroma for chronic pain
   1. Part 1 – Open session
      1. The chair welcomed the invited clinical and patient experts, external group representatives, members of the public and company representatives from Boston Scientific.
      2. The chair asked all committee members to declare any relevant interests in relation to the item being considered.

* No conflicts of interest were declared for the technology.
* The Committee was asked whether there were any specific equalities issues to consider in relation to this procedure.
  + 1. The Chair then introduced Colin Howie, who gave a presentation on the safety and efficacy of Percutaneous image-guided cryoablation of peripheral neuroma for chronic pain.
  1. Part 2 – Closed session

Company representatives, clinical and patient experts and members of the public were asked to leave the meeting at 11:10.

* + 1. The committee then made its provisional recommendations on the safety and efficacy of the procedure. The committee decision was reached by consensus..
    2. The committee asked the NICE technical team to prepare the Consultation Document [IPCD] in line with their decisions.

A document explaining the draft recommendations will be available here: <https://www.nice.org.uk/process/pmg28/chapter/draft-recommendations>

1. Public Consultation comments of IP1856 Transcutaneous electrical neuromuscular stimulation for urinary incontinence
   1. Part 1 – Open session
      1. The chair welcomed the invited clinical and patient experts, external group representatives and members of the public.
      2. The chair asked all committee members to declare any relevant interests in relation to the item being considered.

* Dawn Lee declared an indirect interest as she has worked for a company that makes a spinal stimulator device for urinary incontinence, which could be an alternative to the procedure under consideration.
* It was agreed that her declaration would prevent Dawn Lee from participating in Part 2 of this item.
* The Committee was asked whether there were any specific equalities issues to consider in relation to this procedure.
  + 1. The Chair then summarised the comments received during the consultation on the draft guidance for Transcutaneous electrical neuromuscular stimulation for urinary incontinence.
    2. The Chair introduced the key themes arising from the consultation responses to the Interventional Procedures Consultation Document [IPCD] received from stakeholders and through the NICE website.
  1. Part 2 – Closed session

Company representatives, clinical and patient experts and members of the public were asked to leave the meeting at 11:46.

* + 1. The committee then made its final recommendations on the safety and efficacy of the procedure. The committee decision was reached by consensus..
    2. The committee asked the NICE technical team to prepare the Final Document [FIPD] in line with their decisions.

A document explaining the final recommendations is available here: <https://www.nice.org.uk/process/pmg28/chapter/the-production-of-guidance>

1. NNP of IP1782 Transcutaneous electrical stimulation of the trigeminal nerve for ADHD
   1. Part 1 – Open session
      1. The chair welcomed the invited clinical and patient experts, external group representatives and members of the public.
      2. The chair asked all committee members to declare any relevant interests in relation to the item being considered.

* Insert declarations, including any for committee members who are absent due to conflicts. If none then state that no conflicts of interest were declared for the technology.
* The Committee was asked whether there were any specific equalities issues to consider in relation to this procedure.
  + 1. The Chair then introduced James Tysome, who gave a presentation on the safety and efficacy of Transcutaneous electrical stimulation of the trigeminal nerve for ADHD.
  1. Part 2 – Closed session

Company representatives, clinical and patient experts and members of the public were asked to leave the meeting at 12:27.

* + 1. The committee then made its provisional recommendations on the safety and efficacy of the procedure. The committee decision was reached by consensus..
    2. The committee asked the NICE technical team to prepare the Consultation Document [IPCD] in line with their decisions.
    3. A document explaining the draft recommendations will be available here: <https://www.nice.org.uk/process/pmg28/chapter/draft-recommendations>

1. Public Consultation comments of IP1797 Focal resurfacing implants to treat articular cartilage damage in the knee
   1. Part 1 – Open session
      1. The chair welcomed the invited clinical and patient experts, external group representatives, members of the public and company representatives from Episurf.
      2. The chair asked all committee members to declare any relevant interests in relation to the item being considered.

* No conflicts of interest were declared for the technology.
* The Committee was asked whether there were any specific equalities issues to consider in relation to this procedure.
  + 1. The Chair then summarised the comments received during the consultation on the draft guidance for Focal resurfacing implants to treat articular cartilage damage in the knee.
    2. The Chair introduced the key themes arising from the consultation responses to the Interventional Procedures Consultation Document [IPCD] received from consultees, commentators and through the NICE website.
  1. Part 2 – Closed session

Company representatives, clinical and patient experts and members of the public were asked to leave the meeting at 12:51.

* + 1. The committee then made its final recommendations on the safety and efficacy of the procedure. The committee decision was reached by consensus.
    2. The committee asked the NICE technical team to prepare the Final Document [FIPD] in line with their decisions.
    3. A document explaining the final recommendations will be available here: <https://www.nice.org.uk/process/pmg28/chapter/the-production-of-guidance>

1. Public Consultation comments of IP1858 Superficial venous arterialisation and selective venous occlusion for chronic limb threatening ischaemia in people with no other option for revascularisation
   1. Part 1 – Open session
      1. The chair welcomed the invited clinical and patient experts, external group representatives and members of the public.
      2. The chair asked all committee members to declare any relevant interests in relation to the item being considered.

* No conflicts of interest were declared for the technology.
* The Committee was asked whether there were any specific equalities issues to consider in relation to this procedure.
  + 1. The Chair then introduced Marwan Habib, who summarised the comments received during the consultation on the draft guidance for Superficial venous arterialisation and selective venous occlusion for chronic limb threatening ischaemia in people with no other option for revascularisation.
    2. The Chair introduced the key themes arising from the consultation responses to the Interventional Procedures Consultation Document [IPCD] received from consultees, commentators and through the NICE website.
  1. Part 2 – Closed session

Company representatives, clinical and patient experts and members of the public were asked to leave the meeting at 13:01.

* + 1. The committee then made its final recommendations on the safety and efficacy of the procedure. The committee decision was reached by consensus..
    2. The committee asked the NICE technical team to prepare the Final Document [FIPD] in line with their decisions.

A document explaining the final recommendations will be available here: <https://www.nice.org.uk/process/pmg28/chapter/the-production-of-guidance>

1. Public Consultation comments of IP1316/2 Biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancer
   1. Part 1 – Open session
      1. The chair welcomed the invited clinical and patient experts, external group representatives, members of the public and company representatives from Palette Life Sciences and Boston Scientific.
      2. The chair asked all committee members to declare any relevant interests in relation to the item being considered.

* Dawn Lee declared a direct interest as she works for a company that has worked on the production of budget impact and cost-effectiveness model for Boston Scientific SpaceOAR hydrogel for prostate cancer.
* It was agreed that her declaration would prevent Dawn Lee from participating in this section of the meeting and she was asked to leave the meeting for the duration of the item.
* The Committee was asked whether there were any specific equalities issues to consider in relation to this procedure.
  + 1. The Chair then introduced Matthew Bown, who summarised the comments received during the consultation on the draft guidance for Biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancer.
    2. The Chair introduced the key themes arising from the consultation responses to the Interventional Procedures Consultation Document [IPCD] received from consultees, commentators and through the NICE website.
  1. Part 2 – Closed session

Company representatives, clinical and patient experts and members of the public were asked to leave the meeting at 14:34.

* + 1. The committee then made its final recommendations on the safety and efficacy of the procedure. The committee decision was reached by consensus.
    2. The committee asked the NICE technical team to prepare the Final Document [FIPD] in line with their decisions.

A document explaining the final recommendations will be available here: <https://www.nice.org.uk/process/pmg28/chapter/the-production-of-guidance>

1. Briefs of IP1783 Radiofrequency ablation for palliation of painful spinal metastases
   1. Part 1 – Closed session
      1. The chair asked all committee members to declare any relevant interests in relation to the item being considered.

* Insert declarations, including any for committee members who are absent due to conflicts. If none then state that no conflicts of interest were declared for the technology.
* The Committee was asked whether there were any specific equalities issues to consider in relation to this procedure.
  + 1. The Chair then introduced Jon Bell, who gave a presentation on the safety and efficacy of Radiofrequency ablation for palliation of painful spinal metastases.
    2. The committee approved the content of the scope as adequate for evaluation of this procedure.

1. Briefs of IP1953 Radiofrequency ablation as an adjunct to balloon kyphoplasty or percutaneous vertebroplasty for palliation of painful spinal metastases
   1. Part 1 – Closed session
      1. The chair asked all committee members to declare any relevant interests in relation to the item being considered.

* No conflicts of interest were declared for the technology.
* The Committee was asked whether there were any specific equalities issues to consider in relation to this procedure.
  + 1. The Chair then introduced Jon Bell, who gave a presentation on the safety and efficacy of Radiofrequency ablation as an adjunct to balloon kyphoplasty or percutaneous vertebroplasty for palliation of painful spinal metastases.
    2. The committee approved the content of the scope as adequate for evaluation of this procedure.

1. Briefs of IP863/2 Targeted temperature management to improve neurological outcomes after cardiac arrest
   1. Part 1 – Closed session
      1. The chair asked all committee members to declare any relevant interests in relation to the item being considered.

* No conflicts of interest were declared for the technology.
* The Committee was asked whether there were any specific equalities issues to consider in relation to this procedure.
  + 1. The Chair gave a presentation on the safety and efficacy of Targeted temperature management to improve neurological outcomes after cardiac arrest.
    2. The committee approved the content of the scope as adequate for evaluation of this procedure.

1. Date of the next meeting

The next meeting of the Interventional Procedures Advisory Committee (IPAC) will be held on 14/07/2022 and will start promptly at 9am.